Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
Efficient assessment of drug safety and toxicity can be a complex and time consuming matter.
High quality – our safety pharmacology experts perform the studies on validated platforms
Save time - no assay optimization and data analysis needed – let our experts do this for you
Reliable – assays are based on fully functional and validated hiPSC-derived cardiomyocytes
Versatile – we offer a broad range of optimized assays on various platforms
Flexible – we will make sure to meet your specific needs
An acute CiPA-like MEA analysis
Delivers and acute cardiac safety profile of your compounds following the current protocols of the CiPA initiative for microelectrode arrays (MEA) analysis.
Longer-term cardiotoxicity assessment utilising an electrophysiological and impedance assay system
An (electro)physiological assessment of the potentially longer-term (0-48 hours) toxic effects of your compounds on hiPSC-derived cardiomyocytes as measured by a combination of electrophysiology and impedance.
Multiplex of functional and structural cardiotoxicity
A multiparametric approach to deliver an extensive cardiotoxicity profile of your compounds. This service includes an analysis by impedance (contractility), electrophysiology and biomarker release (structural).
Impedance Assay for Longer Term Cardiac Liability Assessment
Delivers a cost-effective, long-term cardiac safety profile based on label-free impedance analysis. Ideal for screening large numbers of compounds.
Industry’s first true contractile force measurement
Provides true force measurement to study the effect of drug candidates on the contractility and force-frequency relationships of hiPSC-derived cardiomyocyte.
Calcium Transient Analysis of Acute Drug Effects
High-throughput screening of acute drug effects on cardiomyocyte electrophysiology by analyzing the intracellular calcium transients.
Structural toxicity analysis
Delivers a structural cardiotoxicity profile of your compounds based on the release of the cardiac specific biomarker Troponin I by hiPSC-derived cardiomyocytes.
Did not find what you were looking for? Are you interested in a different cell model like endothelial cells, smooth muscle cells or neural cells? Or more interested in biochemical characterization of your cell model?
Let us know what your needs are and we will develop a customized service for you.